Richter Gedeon Nyrt. Stock (HU0000123096): Upcoming Dividend Ex-Date Set for June 3, 2026

Richter Gedeon Nyrt., a leading Hungarian pharmaceutical firm, has scheduled its next dividend ex-date for June 3, 2026, with payment on June 11, offering a current yield of around 3.6%. U.S. investors can access the stock via OTC markets, providing exposure to Eastern European pharma growth.

Richter Gedeon Nyrt. has confirmed its upcoming dividend schedule, with the ex-dividend date set for June 3, 2026, and payment to follow on June 11, 2026. The current dividend yield stands at approximately 3.6%, according to data from Simply Wall St as of April 2026. This announcement provides a clear timeline for shareholders seeking income from the Hungarian pharmaceutical company's stock, traded under ISIN HU0000123096.

The dividend details reflect Richter Gedeon Nyrt.'s ongoing commitment to returning capital to investors amid its operations in pharmaceuticals and biotech. U.S. retail investors interested in international dividend plays may find accessibility through over-the-counter trading venues, where the stock is available alongside its primary listing on the Budapest Stock Exchange.

As of April 29, 2026

By the AD HOC NEWS editorial team – specialist desk for pharmaceutical stocks.

At a glance

• Name: Richter Gedeon Nyrt.
• ISIN: HU0000123096
• Sector/industry: Pharmaceuticals & Biotech
• Headquarters/country: Hungary
• Key markets: Europe, with global reach
• Main revenue drivers: Prescription drugs, women's health products
• Primary listing/trading venue: Budapest Stock Exchange
• Trading currency: Hungarian Forint (HUF), with currency risk for USD investors
• Dividend: Yield ~3.6%, ex-date June 3, 2026

How Richter Gedeon Nyrt. makes money

Richter Gedeon Nyrt. generates revenue primarily through the development, manufacturing, and sale of pharmaceutical products, focusing on areas such as women's health, central nervous system disorders, and cardiovascular treatments. The company operates production facilities in Hungary and distributes its portfolio to over 100 countries, leveraging a mix of branded and generic medicines.

In Hungary, Richter Gedeon Nyrt. ranks as the second-largest company by revenue, reporting $3.9 billion in total revenue according to ZoomInfo data for April 2026. This scale underscores its dominant position in the domestic market while pursuing international expansion.

The business model emphasizes research and development investment alongside contract manufacturing services, allowing diversification beyond core drug sales. Partnerships with global firms help distribute products in regulated markets.

The key revenue and product drivers for Richter Gedeon Nyrt.

Key products include hormonal contraceptives and treatments for gynecological conditions, which form a significant portion of sales. The company's revenue reached $3.9 billion, positioning it as a top manufacturer in Hungary per April 2026 data.

Over the past year, the stock has shown a price change of 18.1%, with a 52-week range from 9,380 HUF to 13,400 HUF, based on historical data from Investing.com. This performance highlights volatility tied to product launches and market dynamics.

Dividend policy remains a core driver, with the upcoming ex-date on June 3, 2026, supporting a yield of 3.6%. Future projections suggest a potential yield of 6.2%, indicating possible growth in payouts.

Industry trends and competitive position

The European pharmaceuticals sector is experiencing steady demand for generics and specialty drugs, where Richter Gedeon Nyrt. competes effectively. Trends include rising focus on biosimilars and women's health innovations, areas where the company has established expertise.

Competitors in similar segments include firms like UCB SA, a biopharma player in neurology and immunology. Richter Gedeon Nyrt. differentiates through its strong Eastern European base and cost-efficient production.

Hungary's manufacturing sector growth supports Richter Gedeon Nyrt.'s operations, with the company contributing significantly to national revenue rankings.

Why Richter Gedeon Nyrt. matters for U.S. investors

U.S. investors can trade Richter Gedeon Nyrt. stock over-the-counter, gaining exposure to a high-yield dividend payer in the pharma sector without direct Budapest exchange access. The 3.6% yield offers income potential amid HUF currency fluctuations against the USD.

With $3.9 billion in revenue, the company provides a window into Eastern Europe's manufacturing boom, relevant for diversified portfolios tracking global pharma trends. Peers like U.S.-listed firms in biotech offer comparable exposure.

Currency risk from HUF trading is a key factor, as dollar-based investors monitor forex impacts on returns.

Which investor profile fits Richter Gedeon Nyrt. stock — and which may not

Income-oriented investors comfortable with emerging market volatility may align with Richter Gedeon Nyrt.'s dividend profile and pharma focus. The upcoming June 2026 ex-date appeals to those seeking regular payouts.

Those preferring U.S.-centric or low-currency-risk holdings might look elsewhere, given the HUF exposure and OTC trading dynamics. Growth investors could note the 18.1% annual stock change.

Risks and open questions for Richter Gedeon Nyrt.

Currency volatility between HUF and USD poses risks for U.S. holders, potentially eroding dividend value. Regulatory changes in European pharma markets could impact product approvals.

Competition in generics and biosimilars remains intense, with firms like UCB SA advancing in adjacent areas. Revenue concentration in key products warrants monitoring.

Next items to watch

• June 3, 2026: Dividend ex-date
• June 11, 2026: Dividend payment date

Bottom line

Richter Gedeon Nyrt.'s dividend ex-date of June 3, 2026, highlights its appeal for income-focused portfolios, with a 3.6% yield noted in April 2026 data. The company's $3.9 billion revenue underscores its manufacturing strength in Hungary. U.S. investors gain international pharma access via OTC trading, balancing yield against currency risks.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.